https://librepathology.org/w/index.php?action=history&feed=atom&title=Antiphospholipid_antibody_syndrome 2026-05-09T07:54:41Z Revision history for this page on the wiki MediaWiki 1.36.3 https://librepathology.org/w/index.php?title=Antiphospholipid_antibody_syndrome&diff=10201&oldid=prev 2011-12-04T16:46:03Z

<p>more</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 16:46, 4 December 2011</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>'''Antiphospholipid antibody syndrome''', also '''antiphospholipid syndrome''', is a thingy commonly seen in the context of [[systemic lupus erythematosus]].&lt;ref name=pmid9814675&gt;{{Cite journal  | last1 = Asherson | first1 = RA. | title = The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. | journal = Lupus | volume = 7 Suppl 2 | issue =  | pages = S55-62 | month =  | year = 1998 | doi =  | PMID = 9814675 }}&lt;/ref&gt; It is commonly abbreviated '''APLA'''.</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>'''Antiphospholipid antibody syndrome''', also '''antiphospholipid syndrome''', is a thingy commonly seen in the context of [[systemic lupus erythematosus]].&lt;ref name=pmid9814675&gt;{{Cite journal  | last1 = Asherson | first1 = RA. | title = The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. | journal = Lupus | volume = 7 Suppl 2 | issue =  | pages = S55-62 | month =  | year = 1998 | doi =  | PMID = 9814675 }}&lt;/ref&gt; It is commonly abbreviated '''APLA'''.</div></td></tr> <tr><td colspan="2"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr> <tr><td colspan="2"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">==General==</ins></div></td></tr> <tr><td colspan="2"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Hypercoagulable state.</ins></div></td></tr> <tr><td colspan="2"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*See: ''[[Pulmonary_embolism#Risks_factors_.28VTE.29|Pulmonary embolism risk factors]]'' for the [[DDx]].</ins></div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Microscopic==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==Microscopic==</div></td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>:See: ''[[Thrombotic microangiopathy#Microscopic|<del style="font-weight: bold; text-decoration: none;">thrombotic </del>microangiopathy]]''.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>:See: ''[[Thrombotic microangiopathy#Microscopic|<ins style="font-weight: bold; text-decoration: none;">Thrombotic </ins>microangiopathy]]''.</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==See also==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==See also==</div></td></tr> </table>

Michael https://librepathology.org/w/index.php?title=Antiphospholipid_antibody_syndrome&diff=10197&oldid=prev 2011-12-04T16:40:14Z

<p>create</p> <p><b>New page</b></p><div>'''Antiphospholipid antibody syndrome''', also '''antiphospholipid syndrome''', is a thingy commonly seen in the context of [[systemic lupus erythematosus]].&lt;ref name=pmid9814675&gt;{{Cite journal | last1 = Asherson | first1 = RA. | title = The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. | journal = Lupus | volume = 7 Suppl 2 | issue = | pages = S55-62 | month = | year = 1998 | doi = | PMID = 9814675 }}&lt;/ref&gt; It is commonly abbreviated '''APLA'''.<br /> <br /> ==Microscopic==<br /> :See: ''[[Thrombotic microangiopathy#Microscopic|thrombotic microangiopathy]]''.<br /> <br /> ==See also==<br /> *[[Systemic lupus erythematosus]].<br /> <br /> ==References==<br /> {{Reflist|1}}<br /> <br /> [[Category:Clinical]]</div>

Michael